← Back to Search

Dietary Supplement

RGMA001 for Non-alcoholic Fatty Liver Disease

N/A
Waitlist Available
Led By John Poulos, MD
Research Sponsored by Biovil Research Group, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 weeks
Awards & highlights

Summary

A research study of a compound containing vitamin E, silymarin and carnitine, three over the counter supplements. The investigators hope to learn if the new supplement can safely and successfully treat fatty liver disease or Non Alcoholic Fatty Liver Disease (NAFLD).

Eligible Conditions
  • Non-alcoholic Fatty Liver Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Efficacy
Secondary study objectives
Safety

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: RGMA001Active Control1 Intervention
Proprietary blend of Vitamin E, Silymarin, and Carnitine.
Group II: Sugar PillPlacebo Group1 Intervention
No treatment.

Find a Location

Who is running the clinical trial?

Biovil Research Group, LLCLead Sponsor
John Poulos, MDPrincipal InvestigatorCumberland Research Associates
~3 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top